NCT07353567Completed
Long-term Outcomes and Risk Factors of Local Re-Recurrence in Patients
Long-term Outcomes and Risk Factors of Local Re-Recurrence in Patients With Locally Recurrent Rectal Cancer
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
To analyze the long-term oncological outcome and identify independent risk factors for local re-recurrence in patients undergoing radical salvage surgery for locally recurrent rectal cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 298 (actual)
- First submitted
- 9 Dec 2025
- Start date
- Jan 2010
- Primary completion date
- Mar 2025
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Diseases
- Childhood cancers
- NCT number
- NCT07353567
What you commit to
- Study type: Observational
- Participants enrolled: 298
- From Jan 2010 to the primary completion date, Mar 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- (2). R2 resection for LRRC;
Other illness
- (1). History of synchronous or metachronous other primary malignancies;
Other
- (3). Presence of uncontrollable synchronous distant metastasis at the time of either primary tumor treatment or LRRC diagnosis;
- (4). Patients lost to follow-up or lacking essential survival data.
Who the study is looking for
- (1). Patients had undergone curative-intent resection for a histologically confirmed primary rectal or rectosigmoid adenocarcinoma. A disease-free interval ≥1 months was required to distinguish subsequent local recurrence from persistent disease;
- (2). LRRC located within the true pelvis or at the pelvic brim, confirmed by radiological imaging (e.g., MRI, CT, PET-CT) and/or pathological verification;
- (3). Patients who underwent radical salvage surgery (R0/R1) for LRRC. No evidence of residual disease or early second recurrence was observed within 1 months after salvage surgery.
- (4). Availability of complete clinicopathological and treatment-related data.
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.